LR invests over €2 million in quality and growth
Global demand for innovative health products continues to grow, and with it the requirements for quality, supply reliability and production capacity. LR Health & Beauty is therefore strengthening its Ahlen headquarters with an investment of more than €2 million, laying the foundation for further growth.
At the heart of the investment is a new, state-of-the-art production line. LR will use it to fully consolidate the manufacturing of its successful 5-in-1 products at its Ahlen headquarters. This includes, among others, the LR 5in1 Beauty Elixir and the LR 5in1 Men’s Shot. At the same time, the new facility creates the conditions for future product innovations in modern nutritional supplement concepts.
By bringing the complete production of its 5-in-1 range to Ahlen, LR is taking an even greater share of its value chain in-house. This enhances control over quality and operational processes, improves flexibility in supplying international markets, and reinforces the company’s independence. It also represents a clear commitment to Germany as a production location and to the highest “Made in Germany” quality standards.
“We are investing strategically in the future of our company and in our Ahlen production site. The new production line represents an important milestone in our continuous investment in quality, state-of-the-art manufacturing capabilities, and sustainable competitiveness. ‘Made in Germany’ is much more than a designation of origin for us – it is a fundamental commitment to quality for our customers and sales partners worldwide,” says Jörg Körfer, CEO of LR Health & Beauty.
The new production line is designed for an annual capacity of up to 40 million units, opening up significant growth potential for LR in the years ahead. The fully automated system combines high production speed, maximum efficiency and stable, reproducible processes. It uses cutting-edge technology from one of the world’s leading plant manufacturers, ranked among the top 10 in the industry.